Skip to main content

Dr. Nall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Nall's full profile

Already have an account?

  • Office

    9113 Leesgate Rd
    Louisville, KY 40222
    Phone+1 502-426-1621
    Fax+1 502-426-7906

Education & Training

  • University of Louisville School of Medicine
    University of Louisville School of MedicineResidency, Pediatrics, 1967 - 1969
  • University of Louisville School of Medicine
    University of Louisville School of MedicineResidency, Pediatrics, 1966 - 1967
  • University of Louisville School of Medicine
    University of Louisville School of MedicineInternship, Transitional Year, 1965 - 1966
  • University of Kentucky College of Medicine
    University of Kentucky College of MedicineClass of 1965

Certifications & Licensure

  • KY State Medical License
    KY State Medical License 1966 - 2025
  • IN State Medical License
    IN State Medical License 2011 - 2019
  • American Board of Allergy and Immunology Allergy & Immunology
  • American Board of Pediatrics Pediatrics

Publications & Presentations

PubMed

Press Mentions

  • Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers
    Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer BiomarkersJuly 6th, 2021
  • Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
    Biocept Reports 2020 Fourth Quarter and Full Year Financial ResultsMarch 29th, 2021
  • Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting
    Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy MeetingOctober 1st, 2020
  • Join now to see all